


Data Sheet

Product Name:	Lusutrombopag
Cat. No.:	CS-6137
CAS No.:	1110766-97-6
Molecular Formula:	C ₂₉ H ₃₂ Cl ₂ N ₂ O ₅ S
Molecular Weight:	591.55
Target:	Thrombopoietin Receptor
Pathway:	Immunology/Inflammation
Solubility:	DMSO : ≥ 33 mg/mL (55.79 mM); H ₂ O : < 0.1 mg/mL (insoluble)



BIOLOGICAL ACTIVITY:

Lusutrombopag is an orally bioavailable **thrombopoietin (TPO) receptor** agonist, used for treatment of chronic liver disease. **In Vitro:** Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels^[1].

References:

[1]. Kim ES, et al. Lusutrombopag: First Global Approval. *Drugs*. 2016 Jan;76(1):155-8.

CAIndexNames:

2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)-

SMILES:

O=C(O)/C(C)=C/C1=C(Cl)C=C(C(NC2=NC(C3=CC=CC([C@@H](OCCCCC)C)=C3OC)=CS2)=O)C=C1Cl

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA